Sio Gene Therapies Inc.
SIOX · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.18 | 0.03 | 0.02 | 0.02 |
| FCF Yield | -16.20% | -24.60% | -33.71% | -36.82% |
| EV / EBITDA | 0.00 | 0.00 | 0.00 | 0.91 |
| Quality | ||||
| ROIC | -8.71% | -6.29% | -15.76% | -21.59% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.22 | 1.65 | 1.03 | 1.34 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -2.28% | 43.11% | 50.73% | 12.37% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 0.00 | 4.70 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -1,659.88 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |